Major Depressive Disorder Clinical Trial
Official title:
Information Technology Enabled Treatment of Adolescent Depression
The purpose of this study is to evaluate a computer-guided, telephone-based therapy for adolescent depression, delivered in a pediatric primary setting in the community.
This Phase II SBIR project represents the continuing development of an Information
Technology Enabled Disease Management System for Treatment of Adolescent Depression (iTAD)
following a highly successful Phase I award in which all Specific Aims were met. The need
for this system innovation arises from the substantial costs that inadequately treated
adolescent Major Depressive Disorder (MDD) has on the course of adolescent development and
society as a whole. Effective treatments involving the combined use of a Selective Serotonin
Reuptake Inhibitor (SSRI) and the administration of Cognitive Behavioral Therapy (CBT) is
considered the "modal treatment" for adolescent MM. Yet, multiple barriers interfere with
the implementation and dissemination of this "gold standard' of care. These barriers
include: under recognition of depressive symptoms by parents and pediatricians, inability to
assess adolescent depression accurately and reliably in primary care settings, safety
concerns related to pharmacologic treatment, monitoring of symptom changes and adverse
treatment effects, such as irritability and suicidal behavior, treatment non-compliance,
lack of access to an integrated medical and treatment history; and an alarming shortage of
properly trained child and adolescent psychiatrists capable of implementing optimal
treatment safely, reliably, and effectively.
In this current project, the investigators are making tailored forms of CBT broadly and
easily accessible to the community, using the iTAD (previously "ITEMS-TAD") which is
intended to address these problems. Development of the system has continued and we have
modified the existing prototype that was created with funding from federal sources (Phase
1). The technological infrastructure of the prototype includes a Computer Assisted Telephone
Interview (CATI) platform, a database consisting of patients' real time medical and
treatment history, and an underlying set of intelligent algorithms that tailors the
intensity of the treatment resources and approaches administered in individual cases, with a
special focus on identifying those enrolled adolescents needing more intensive or urgent
care. When interacting with patients over the telephone, primary care nurses use the CATI to
facilitate the reliable assessment of patient status and administer manualized, empirically
informed interventions. The programming for the platform that delivers this intervention is
complete and the debugging and refinement underway. The content for the remaining iTAD
program has been developed and is being programmed. A Rapid Iterative Evaluation & Testing
(RITE) study was undertaken to refine the content of the application and assess the
usability of the technology involved in its delivery; A field trial is underway to evaluate
empirically indicators of efficacy and patient acceptance related to the ITEMS-TAD approach.
The clinical trial of iTAD will begin in early April 2012. The investigators are currently
enrolling depressed adolescents who will begin the trial shortly.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |